Sustained release profiles and targeted delivery of pharmaceutical products
A matrix tablet is coated with functional polymers, followed by a blend of hydrophilic and hydrophobic polymers. Layered erosion and diffusion of the drug matrix tablet result in a controllable release. An effective solution for targeted drug delivery through customized and sustained release technology. Assists development of high-dosage and sustained release products for once-daily administration.
Customized release profiles, including zero-order release
This technology incorporates a blend of hydrophilic polymers that control drug release via diffusion through, and erosion of, a matrix tablet. Some layers contain drug substance; others are rate controlling polymers.
Key Benefits
- Matrix tablet utilizes a combination of water soluble particles and active drug
- Suitable for high drug loading
- Supports sustained release, once a day dosing
Speak With An Expert
Srinivasan Shanmugam, Ph.D
Senior Director, Pharmaceutical Sciences, Business Support, and New Technologies
Dr. Srinivasan Shanmugam is involved in the development and expansion of Adare’s pharmaceutical technology portfolio and supports product development, co-development, and tech transfer opportunities. Dr. Shanmugam has a Ph.D. M.S., and a B.S. in Pharmacy. Dr. Shanmugam has more than 20 years of experience in designing and development of conventional, NDDS/alternate, advanced/modified drug delivery systems, and pharmaceutical platform technologies for oral and other routes of administration. His expertise includes enabling technologies for challenging drugs and developing platform technologies. Additionally, his expertise includes patient-centric solutions focusing on pediatric and geriatric populations to achieve dose convenience, flexibility, and precision. Dr. Shanmugam has published numerous research articles, holds multiple patents, and is a reviewer/editorial member of various prestigious journals. Shanmugam’s recent work focuses on product development solutions for special patient populations like pediatric and geriatric populations.
